Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$80 Mln
P/E Ratio
--
P/B Ratio
2.96
Industry P/E
35.57
Debt to Equity
0
ROE
-0.82 %
ROCE
--
Div. Yield
0 %
Book Value
0.18
EPS
-0.27
CFO
$-168.67 Mln
EBITDA
$-233.07 Mln
Net Profit
$-223.89 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Veru (VERU)
| -17.29 | 0.58 | -55.54 | -59.24 | -63.66 | -30.55 | -15.93 |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Veru (VERU)
| -9.58 | -86.36 | -10.36 | -31.91 | 158.21 | 139.29 | 22.67 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 4.97 | 4,333.81 | -- | -0.28 | |
| 30.82 | 1,477.25 | 16.65 | 5.96 | |
| 108.45 | 3,483.84 | 21.18 | 22.76 | |
| 1.30 | 885.46 | 43.33 | 2.27 |
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom... for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Read more
Chairman, President & CEO
Dr. Mitchell S. Steiner F.A.C.S., M.D.
Chairman, President & CEO
Dr. Mitchell S. Steiner F.A.C.S., M.D.
Headquarters
Miami, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Veru Inc (VERU) stood at $ 46 Mln as on 31-Dec-24
The share price of Veru Inc (VERU) is $0.54 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Veru Inc (VERU) has given a return of -63.66% in the last 3 years.
Veru Inc (VERU) has a market capitalisation of $ 80 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Veru Inc (VERU) is 2.96 times as on 25-Apr-2025, a 58% discount to its peers’ median range of 7.12 times.
Since, TTM earnings of Veru Inc (VERU) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Veru Inc (VERU) and enter the required number of quantities and click on buy to purchase the shares of Veru Inc (VERU).
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
The CEO & director of Dr. Mitchell S. Steiner F.A.C.S., M.D.. is Veru Inc (VERU), and CFO & Sr. VP is Dr. Mitchell S. Steiner F.A.C.S., M.D..
There is no promoter pledging in Veru Inc (VERU).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
430
|
|
|
346
|
|
|
147
|
|
|
81
|
| Veru Inc. (VERU) | Ratios |
|---|---|
|
Return on equity(%)
|
-119.76
|
|
Operating margin(%)
|
-266.04
|
|
Net Margin(%)
|
-260.9
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Veru Inc (VERU) was $0 Mln.
$-0.01
(
